The primary objective is acquiring insights in the development of BOS in patients after human lung transplantation in an early phase of the disease which can be used to improve immunotherapeutic handling in order to prevent or delay the onset of BOS…
ID
Source
Brief title
Condition
- Other condition
- Viral infectious disorders
- Bronchial disorders (excl neoplasms)
Synonym
Health condition
genetische pathogenese
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Prediction of BOS in patients after human lung transplantation in an early
phase of the disease.
Secondary outcome
Reactivity of T cells against target antigens as detected by the SEREX techique.
Relation of respiratory viruses and the development BOS.
Relation of respiratory viruses and the development of BOS.
Relation of genetic profile and the development of BOS.
Relation of proteins in condensated breath in patients after human lung
transplantation and the development of BOS.
Background summary
Survival after lung transplantation is limited by the occurrence of
obliterative bronchiolitis, which is characterised by the presence of
bronchiolar inflammation and fibrosis in conjunction with progressive airflow
obstruction. The pathogenesis is not well known but is associated with repeated
injury to the graft by ischemia-reperfusion injury, rejection, infection and
inflammatory reactions leading to damage of the airway epithelium followed by
an exaggerated healing response. The development of Bronchiolitis Obliterans is
usually characterized by a poor response to augmented immune suppression, but
may be effective in an early phase of the disease. In this study we will
acquire insights in the multiple immunologic, biological, genetic and
inflammatory effects on the transplanted lung in relation to the development of
BOS.
Study objective
The primary objective is acquiring insights in the development of BOS in
patients after human lung transplantation in an early phase of the disease
which can be used to improve immunotherapeutic handling in order to prevent or
delay the onset of BOS.
Study design
observational cohort study
Study burden and risks
Because of the additional blood samples, a total of 24 x 40 ml in 4 years,
there is a possibility of developing anemia. When this occurs and has
therapeutic consequences the additional blood samples will temporarily be
stopped.
Heidelberglaan 100
Utrecht
NL
Heidelberglaan 100
Utrecht
NL
Listed location countries
Age
Inclusion criteria
Patients who undergo a lung transplantation
Exclusion criteria
none
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL12752.041.06 |